Design Therapeutics (DSGN) Short-term Investments (2020 - 2026)

Design Therapeutics has reported Short-term Investments for 7 years, with the latest figure at $194.5 million in Q2 2026.

• Short-term Investments for Q2 2026 came in at $194.5 million, down 1.06% year-over-year; the trailing twelve-month figure through Jun 2026 was $194.5 million (down 1.06% YoY), and the FY2025 annual result was $203.0 million, down 8.94% from the prior year.
• Short-term Investments retreated to $194.5 million in Q2 2026, from $210.1 million in the prior quarter.
• Over five years, Short-term Investments peaked at $303.9 million in Q4 2022 and troughed at $83.9 million in Q1 2022.
• A 5-year average of $229.4 million and a median of $223.3 million in 2024 frame the typical range for Short-term Investments.
• The widest annual swing landed in 2022, when Short-term Investments surged 736.8%; it then fell 21.96% in 2024.
• A 5-year view of Short-term Investments shows it stood at $303.9 million in 2022, then declined by 14.25% to $260.6 million in 2023, then slipped by 14.46% to $222.9 million in 2024, then retreated by 8.94% to $203.0 million in 2025, then fell by 4.19% to $194.5 million in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $194.5 million in Q2 2026, $210.1 million in Q1 2026, and $203.0 million in Q4 2025.